quinacrine has been researched along with Carcinoma, Renal Cell in 1 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurova, KV | 1 |
| Hill, JE | 1 |
| Guo, C | 1 |
| Prokvolit, A | 1 |
| Burdelya, LG | 1 |
| Samoylova, E | 1 |
| Khodyakova, AV | 1 |
| Ganapathi, R | 1 |
| Ganapathi, M | 1 |
| Tararova, ND | 1 |
| Bosykh, D | 1 |
| Lvovskiy, D | 1 |
| Webb, TR | 1 |
| Stark, GR | 1 |
| Gudkov, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer[NCT00417274] | Phase 2 | 31 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who achieved a complete response (CR) or a partial response (PR) to therapy were allowed to continue to receive treatment until disease progression or unacceptable toxicity occurred, until the patient discontinued treatment for another reason, or for a total of 6 months. Patients who continued to show a CR or PR or who maintained stable disease (SD) after 6 months of therapy were to be allowed to continue therapy at the investigator's discretion. (NCT00417274)
Timeframe: End of treatment
| Intervention | Participants (Number) |
|---|---|
| Quinacrine Treatment | 1 |
1 other study available for quinacrine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.
Topics: Aminacrine; beta-Galactosidase; Carcinoma, Renal Cell; Cell Line, Tumor; Colorimetry; Gene Expressio | 2005 |